The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 2×
“Patients with these classical mutations tend to have favourable responses to EGFR TKIs 12,13 .”
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 2×
“Patients with these classical mutations tend to have favourable responses to EGFR TKIs 12,13 .”
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 5×
“Adverse events associated with wild-type EGFR (such as rash and diarrhoea) are less frequent compared to first-generation and second-generation EGFR TKIs owing to the lower activity of these agents against wild-type EGFR 27–32 .”
InfluentialSelf-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · cited 1×
“For instance, the mutations L718Q, S768I and T854I occur in exons 18, 20 and 21, respectively, but are categorized as PACC mutations owing to their similar structural effect on drug binding.”
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Initial trials that assessed the efficacy of EGFR TKIs in unselected patients with NSCLC have shown only modest benefits compared to placebo 11 .”
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · cited 2×
“For instance, the mutations L718Q, S768I and T854I occur in exons 18, 20 and 21, respectively, but are categorized as PACC mutations owing to their similar structural effect on drug binding.”
InfluentialZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · cited 1×
“The introduction of first-generation EGFR TKIs (such as erlotinib, gefitinib and icotinib) brought about a groundbreaking shift in the treatment landscape for patients with metastatic NSCLC harbouring common sensitizing mutations in EGFR 17–21 .”
Self-citationTumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825 · cited 1×
“%) reported in those with early stage NSCLC harbouring wild-type EGFR and ALK receiving neoadjuvant ICIs plus chemotherapy 106–110 .”
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“• T790M in exon 20 is the most common mutation acquired upon resistance to first-generation and second-generation EGFR TKIs (occurring in between 50% and 60% of patients with resistance) 267,268 .”
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“However, the development of resistance, particularly through the emergence of the T790M gatekeeper mutation 22 , has posed a substantial clinical challenge.”
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Self-citationSpigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01308 · Cited by 1,445
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191 · cited 1×
“However, we must acknowledge that the sensitivity and specificity of ctDNA assays can fluctuate and the risk of false-positive or false-negative results exists 262 .”
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · cited 1×
“predictive biomarkers, reinforcing the value of personalized medicine in guiding therapeutic decisions and improving patient outcomes 6 .”
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002 · cited 4×
“Notably, the L861Q mutation is associated with particular sensitivity to the second-generation EGFR TKI afatinib 33 and third-generation EGFR TKIs 14 .”
InfluentialSelf-citationAcquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“Acquired EGFR amplification often co-occurs with T790M mutations following resistance to first-generation EGFR TKIs 132 , although its direct role in resistance remains unclear.”
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686 · cited 1×
“Rare genetic events, such as gene fusions and/or chromosomal rearrangements involving genes including RET , ALK , BRAF , FGFR and ROS1 can also mediate resistance to osimertinib 144–148 .”
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658 · cited 1×
“PROTACs primarily exert their therapeutic effects by inducing polyubiquitination of pathogenic target proteins, which leads to the degradation of the entire protein of interest via the ubiquitin–proteasome system 246 .”
Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2310 · Cited by 542
Self-citationMarcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01585 · Cited by 500 · cited 2×
“…transformation, which occurs in up to 15% of EGFR -mutant NSCLCs that progress following osimertinib treat-ment 8,177,178 , is associated with TP53 and/or RB1 loss 179 , oncogenic mutations in PIK3CA and NOTCH 180 , and activation of MYC 181 , AKT 167 and the transcription factor ASCL1 182 .”
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490 · cited 6×
“In the past few years, studies that have addressed structure–function relationships have indicated that second-generation TKIs have greater selectivity than third-generation TKIs for EGFR variants with PACC mutations (including G719X, L747X and S768I, among others) 14,16 .”
InfluentialSelf-citationCho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358 · cited 1×
“The evolving data on the effectiveness of osimertinib in this patient population also under-scores the potential of osimertinib as a promising therapeutic option for patients with uncommon EGFR mutations 35,36 , particularly L861Q 14 .”
Targeting Cancer Cell Dormancy
Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356
Altorki, N. K., McGraw, T. E., Borczuk, A. C., Saxena, A., Port, J. L., Stiles, B. M., Lee, B. E., Sanfilippo, N. J., Scheff, R. J., Pua, B. B., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00149-2 · Cited by 342
Wu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7326 · Cited by 333
Self-citationYun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297 · cited 1×
“Amivantamab has demonstrated antitumour activity in NSCLC harbouring various EGFR mutations 54 , including EGFR exon20ins 55,56 , becoming an alternative treatment option for these patients.”
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256 · cited 5×
“The prevailing theory suggests that tumour plasticity originates from drug-tolerant persister cells (DTPs) and cancer stem cells (CSCs) 190 , as discussed in the following section.”
InfluentialChiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000504 · Cited by 241 · cited 1×
“• The S768I mutations have moderate responses to first-generation EGFR TKIs 275 but are sensitive to afatinib 33 .”
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1486 · Cited by 228
Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000048 · Cited by 204
Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186 · cited 1×
“This difference has been attributed to an immune phenotype referred to as ‘immune cold’ tumours 226 .”
Self-citationEGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · cited 1×
“Knockdown of MIG6 has been shown to enhance the proliferation of cultured cancer cells under hypoxia, a hallmark of resistance to anticancer therapy 217 and stimulate ERK and AKT phosphorylation by increasing EGFR–HER3 binding 218 .”
Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Heigener, D. F., Schumann, C., Sebastian, M., Sadjadian, P., Stehle, I., Märten, A., Lüers, A., Griesinger, F., Scheffler, M., & for the Afatinib Compassionate Use Consortium (ACUC) (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0073 · Cited by 78
Endo, H., Okami, J., Okuyama, H., Nishizawa, Y., Imamura, F., & Inoue, M. (2017) · Oncogene · doi:10.1038/onc.2016.431 · Cited by 50 · cited 1×
“Knockdown of MIG6 has been shown to enhance the proliferation of cultured cancer cells under hypoxia, a hallmark of resistance to anticancer therapy 217 and stimulate ERK and AKT phosphorylation by increasing EGFR–HER3 binding 218 .”
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Metadata
- Authors
- Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2024-11-29
- Volume
- 22
- Issue
- 2
- Pages
- 95-116
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4404839476
- Cited by
- 182
- References
- 47
- FWCI
- 21.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.